{
    "clinical_study": {
        "@rank": "120968", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (cisplatin, EBRT, brachytherapy)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, and 30 of radiation therapy. Patients undergo EBRT five days a week for 5 weeks with a boost in week 6 followed by 5 sessions of HDR brachytherapy once or twice weekly beginning in week 4 or up to 2 sessions of LDR brachytherapy within 3 weeks of completion of EBRT."
            }, 
            {
                "arm_group_label": "Arm II (Triapine, cisplatin, EBRT, brachytherapy)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive Triapine IV over 90-120 minutes on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33 of radiation therapy. Patients also receive cisplatin IV and undergo EBRT and brachytherapy as in Arm I."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase II trial studies how well cisplatin and radiation therapy with or\n      without Triapine work in treating patients with previously untreated stage IB-IVA cervical\n      cancer or stage II-IVA vaginal cancer. Drugs used in chemotherapy, such as cisplatin, work\n      in different ways to stop the growth of tumor cells, either by killing the cells or by\n      stopping them from dividing. Radiation therapy uses high energy x rays to kill tumor cells.\n      Triapine may make tumor cells more sensitive to radiation therapy. It is not yet known\n      whether cisplatin and radiation therapy is more effective when given with or without\n      Triapine in treating cervical or vaginal cancer."
        }, 
        "brief_title": "Cisplatin and Radiation Therapy With or Without Triapine in Treating Patients With Previously Untreated Stage IB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer", 
        "condition": [
            "Cervical Adenocarcinoma", 
            "Cervical Adenosquamous Cell Carcinoma", 
            "Cervical Squamous Cell Carcinoma", 
            "Stage IB Cervical Cancer", 
            "Stage II Vaginal Cancer", 
            "Stage IIA Cervical Cancer", 
            "Stage IIB Cervical Cancer", 
            "Stage III Vaginal Cancer", 
            "Stage IIIA Cervical Cancer", 
            "Stage IIIB Cervical Cancer", 
            "Stage IVA Cervical Cancer", 
            "Stage IVA Vaginal Cancer", 
            "Vaginal Adenocarcinoma", 
            "Vaginal Squamous Cell Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Uterine Cervical Neoplasms", 
                "Vaginal Neoplasms", 
                "Carcinoma, Adenosquamous"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the posttherapy 3-month fludeoxyglucose F 18 (18F-FDG) positron emission\n      tomography (PET)/computed tomography (CT) complete metabolic response of\n      3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) (Triapine) radiochemotherapy.\n\n      SECONDARY OBJECTIVES:\n\n      I. Determining acute < 30 day adverse events of 3-AP radiochemotherapy by Common Terminology\n      Criteria for Adverse Events (CTCAE), version 4.\n\n      II. Determining the late >= 30 day adverse events of 3-AP radiochemotherapy by CTCAE version\n      4.\n\n      III. Determining post-therapy clinical response by Response Evaluation Criteria in Solid\n      Tumors (RECIST), version 1.1.\n\n      IV. Determining the progression-free interval of 3-AP radiochemotherapy. V. Determining\n      peripheral blood methemoglobin proportion before and after 3-AP infusion. (Optional)\n\n      OUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\n      ARM I: Patients receive cisplatin intravenously (IV) over 90 minutes on days 2, 9, 16, 23,\n      and 30 of radiation therapy. Patients undergo external beam radiation therapy (EBRT) five\n      days a week for 5 weeks with a boost in week 6 followed by 5 sessions of high dose rate\n      (HDR) brachytherapy once or twice weekly beginning in week 4 or up to 2 sessions of low dose\n      rate (LDR) brachytherapy within 3 weeks of completion of EBRT.\n\n      ARM II: Patients receive Triapine IV over 90-120 minutes on days 1, 3, 5, 8, 10, 12, 15, 17,\n      19, 22, 24, 26, 29, 31, and 33 of radiation therapy. Patients also receive cisplatin IV and\n      undergo EBRT and brachytherapy as in Arm I.\n\n      In both arms, treatment continues for up to 6 weeks in the absence of disease progression or\n      unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up at 1, 3, and 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients are eligible with untreated squamous, adenosquamous, or adenocarcinoma\n             cancers of stage IB2-IVA carcinoma of the uterine cervix or stage II-IVA vaginal\n             carcinoma not amenable to curative surgical resection; pathological verification of\n             diagnosis must be obtained and recorded; the presence or absence of para-aortic lymph\n             node metastasis will be based on pre-therapy 18F-FDG PET/CT; if the baseline 18F-FDG\n             PET/CT identifies hypermetabolic para-aortic disease, such patients will not be\n             eligible for participation; the patient must be able to tolerate the requirements for\n             18F-FDG PET/CT scanning\n\n          -  Patients must have a Gynecologic Oncology Group (GOG) performance status of 0, 1, or\n             2\n\n          -  Patients must have a life expectancy of greater than 20 weeks\n\n          -  Absolute neutrophil count > 1,500/\u00b5L\n\n          -  Platelets > 100,000/\u00b5L\n\n          -  Hemoglobin > 10 g/dL\n\n          -  Total bilirubin < 2.0 mg/dL\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase\n             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])\n             < 2.5 X institutional upper limit of normal\n\n          -  Creatinine =< 1.5 mg/dL to receive weekly intravenous cisplatin*; *patients whose\n             serum creatinine is between 1.5 and 1.9 mg/dL are eligible for cisplatin if the\n             estimated creatinine clearance is >= 30 ml/min; for the purpose of estimating the\n             creatinine clearance, the formula of Cockcroft and Gault for females should be used\n\n          -  All patients must have measurable cervical cancer or vaginal cancer disease;\n             measurable disease is defined as at least one lesion that can be accurately measured\n             in at least one dimension (longest diameter to be recorded); each lesion must be >=\n             40 mm when measured preferably by clinical exam or alternatively by computed\n             tomography (CT), magnetic resonance imaging (MRI)\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control; abstinence) prior to study entry and\n             for the duration of study participation; should a woman become pregnant or suspect\n             she is pregnant while participating in this study, she should inform her treating\n             physician immediately; if in the investigator's opinion the patient is of\n             child-bearing age, a negative urine pregnancy test must be resulted within 7 days\n             before initiating protocol therapy; women should not breast feed during therapy (or\n             has agreed to discontinue breastfeeding before initiation of therapy)\n\n          -  Patients must have an ability to understand and willingness to sign a written\n             informed consent document\n\n        Exclusion Criteria:\n\n          -  Patients with other active invasive malignancies are excluded; patients with prior\n             malignancies are excluded (except non-melanoma skin cancer or prior in situ carcinoma\n             of the cervix; patients with other invasive malignancies who had [or have] cancer\n             present within the last five years); patients are excluded if they have received\n             prior pelvic radiotherapy for any reason that would contribute radiation dose that\n             would exceed tolerance of normal tissues\n\n          -  Patients who are receiving any other investigational agents\n\n          -  Patients with known brain metastases should be excluded from this clinical trial\n             because of their poor prognosis and because they often develop progressive neurologic\n             dysfunction that would confound the evaluation of neurologic and other adverse events\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to 3-AP (Triapine) or other agents used in study\n\n          -  Uncontrolled intercurrent illness including, but not limited to, symptomatic\n             congestive heart failure, unstable angina pectoris, myocardial infarction within six\n             months of protocol initiation, cardiac arrhythmia, known inadequately controlled\n             hypertension, significant pulmonary disease including dyspnea at rest, patients\n             requiring supplemental oxygen, or poor pulmonary reserve; proteinuria or clinically\n             significant renal function impairment (baseline serum creatinine > 2 mg / dL), or\n             psychiatric illness/social situations that would limit compliance with study\n             requirements are excluded\n\n          -  Patient does not have uncontrolled diabetes mellitus (fasting blood glucose > 200\n             mg/dL)\n\n          -  Patients with known glucose-6-phosphate dehydrogenase deficiency (G6PD) are excluded\n             due to an inability to administer the antidote for methemoglobinemia, methylene blue;\n             testing for G6PD is not required for study enrollment and optional\n\n          -  Known human immunodeficiency virus (HIV)-positive patients receiving combination\n             antiretroviral therapy are ineligible; HIV testing is not required for study\n             enrollment and optional"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "73", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01835171", 
            "org_study_id": "NCI-2013-00804", 
            "secondary_id": [
                "NCI-2013-00804", 
                "NCI 9434", 
                "CASE 4812", 
                "9434", 
                "U01CA062502", 
                "P30CA043703"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm II (Triapine, cisplatin, EBRT, brachytherapy)", 
                "description": "Given IV", 
                "intervention_name": "triapine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "3-AP", 
                    "OCX-191"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm I (cisplatin, EBRT, brachytherapy)", 
                    "Arm II (Triapine, cisplatin, EBRT, brachytherapy)"
                ], 
                "description": "Given IV", 
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CACP", 
                    "CDDP", 
                    "CPDD", 
                    "DDP"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm I (cisplatin, EBRT, brachytherapy)", 
                    "Arm II (Triapine, cisplatin, EBRT, brachytherapy)"
                ], 
                "description": "Undergo EBRT", 
                "intervention_name": "external beam radiation therapy", 
                "intervention_type": "Radiation", 
                "other_name": "EBRT"
            }, 
            {
                "arm_group_label": [
                    "Arm I (cisplatin, EBRT, brachytherapy)", 
                    "Arm II (Triapine, cisplatin, EBRT, brachytherapy)"
                ], 
                "description": "Undergo HDR or LDR brachytherapy", 
                "intervention_name": "brachytherapy", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "low-LET implant therapy", 
                    "radiation brachytherapy", 
                    "therapy, low-LET implant"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm I (cisplatin, EBRT, brachytherapy)", 
                    "Arm II (Triapine, cisplatin, EBRT, brachytherapy)"
                ], 
                "description": "Optional correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cisplatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "canceranswers@moffitt.org", 
                    "last_name": "Patricia L. Judson", 
                    "phone": "800-456-7121"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center and Research Institute"
                }, 
                "investigator": {
                    "last_name": "Patricia L. Judson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "vongruev@summa-health.org", 
                    "last_name": "Vivian E. von Gruenigen", 
                    "phone": "330-379-3514"
                }, 
                "facility": {
                    "address": {
                        "city": "Akron", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44304"
                    }, 
                    "name": "Summa Akron City Hospital/Cooper Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Vivian E. von Gruenigen", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "michenc@ccf.org", 
                    "last_name": "Chad M. Michener", 
                    "phone": "216-444-1712"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic Foundation"
                }, 
                "investigator": {
                    "last_name": "Chad M. Michener", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kunosc@summahealth.org", 
                    "last_name": "Charles A. Kunos", 
                    "phone": "330-375-4485"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Case Western Reserve University"
                }, 
                "investigator": {
                    "last_name": "Charles A. Kunos", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jerald.katcher@uhhospitals.org", 
                    "last_name": "Jerald Katcher", 
                    "phone": "216-896-1755"
                }, 
                "facility": {
                    "address": {
                        "city": "Orange Village", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44122"
                    }, 
                    "name": "UHHS-Chagrin Highlands Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jerald Katcher", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kathleen-moore@ouhsc.edu", 
                    "last_name": "Kathleen N. Moore", 
                    "phone": "405-271-8707"
                }, 
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "University of Oklahoma Health Sciences Center"
                }, 
                "investigator": {
                    "last_name": "Kathleen N. Moore", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jayanthi.lea@utsouthwestern.edu", 
                    "last_name": "Jayanthi S. Lea", 
                    "phone": "214-648-3026"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390"
                    }, 
                    "name": "University of Texas Southwestern Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jayanthi S. Lea", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase II Study of Intravenous 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine\u00ae NSC #663249) Cisplatin-Radiochemotherapy Versus Intravenous Cisplatin-Radiochemotherapy in Women Diagnosed With Stage IB-IVA Cervical Cancer and Stage II-IVA Vaginal Cancer", 
        "overall_official": {
            "affiliation": "Case Western Reserve University", 
            "last_name": "Charles Kunos", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "18F-FDG PET/CT metabolic complete response by European Organization for Research and Treatment of Cancer (EORTC) criteria", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01835171"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Acute (less than 30 day) adverse events, graded according to National Cancer Institute (NCI) CTCAE, version 4", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days"
            }, 
            {
                "measure": "Late (greater than or equal to 30 day) adverse events, graded according to NCI CTCAE v4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Clinical response as measured by RECIST version 1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "description": "Life table analyses as presented by the method of Kaplan and Meier will be used to determine statistical significance using an alpha of 0.05.", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "The time from start of treatment until time of progression, recurrence, or death, assessed up to 6 months"
            }, 
            {
                "measure": "Methemoglobin percentage after Triapine infusion (Optional)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 hours after Triapine infusion"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}